View Item 

Show simple item record

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorBerrocal, Veronica J.en_US
dc.contributor.authorGiannini, Edward H.en_US
dc.contributor.authorSeibold, James R.en_US
dc.contributor.authorMerkel, Peter A.en_US
dc.contributor.authorMayes, Maureen D.en_US
dc.contributor.authorBaron, Murrayen_US
dc.contributor.authorClements, Philip J.en_US
dc.contributor.authorSteen, Virginiaen_US
dc.contributor.authorAssassi, Shervinen_US
dc.contributor.authorSchiopu, Elenaen_US
dc.contributor.authorPhillips, Kristineen_US
dc.contributor.authorSimms, Robert W.en_US
dc.contributor.authorAllanore, Yannicken_US
dc.contributor.authorDenton, Christopher P.en_US
dc.contributor.authorDistler, Oliveren_US
dc.contributor.authorJohnson, Sindhu R.en_US
dc.contributor.authorMatucci‐cerinic, Marcoen_US
dc.contributor.authorPope, Janet E.en_US
dc.contributor.authorProudman, Susanna M.en_US
dc.contributor.authorSiegel, Jeffreyen_US
dc.contributor.authorWong, Weng Keeen_US
dc.contributor.authorWells, Athol U.en_US
dc.contributor.authorFurst, Daniel E.en_US
dc.date.accessioned2016-02-01T18:50:44Z
dc.date.available2017-04-04T14:50:43Zen
dc.date.issued2016-02en_US
dc.identifier.citationKhanna, Dinesh; Berrocal, Veronica J.; Giannini, Edward H.; Seibold, James R.; Merkel, Peter A.; Mayes, Maureen D.; Baron, Murray; Clements, Philip J.; Steen, Virginia; Assassi, Shervin; Schiopu, Elena; Phillips, Kristine; Simms, Robert W.; Allanore, Yannick; Denton, Christopher P.; Distler, Oliver; Johnson, Sindhu R.; Matucci‐cerinic, Marco ; Pope, Janet E.; Proudman, Susanna M.; Siegel, Jeffrey; Wong, Weng Kee; Wells, Athol U.; Furst, Daniel E. (2016). "The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis." Arthritis Care & Research 68(2): 167-178.en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/117241
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherLawrence Erlbaum Associatesen_US
dc.titleThe American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/117241/1/acr22804.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/117241/2/acr22804_am.pdf
dc.identifier.doi10.1002/acr.22804en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111 – 7.en_US
dc.identifier.citedreferencePaulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 477 – 84.en_US
dc.identifier.citedreferenceFelson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727 – 35.en_US
dc.identifier.citedreferenceNair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum 2011; 41: 95 – 105.en_US
dc.identifier.citedreferenceClassification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55: 348 – 52.en_US
dc.identifier.citedreferenceMerkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, et al, for the Scleroderma Clinical Trials Consortium. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta‐analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2012; 64: 3420 – 9.en_US
dc.identifier.citedreferenceWiese AB, Berrocal VJ, Furst DE, Seibold JR, Merkel PA, Mayes MD, et al. Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. Arthritis Care Res (Hoboken) 2014; 66: 1731 – 9.en_US
dc.identifier.citedreferenceHays RD, Hadorn D. Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res 1992; 1: 73 – 5.en_US
dc.identifier.citedreferenceCohen J. The analysis of variance and covariance. In: Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988. p. 273 – 406.en_US
dc.identifier.citedreferenceDavies EH, Surtees R, DeVile C, Schoon I, Vellodi A. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 2007; 30: 768 – 82.en_US
dc.identifier.citedreferenceFan X, Pope J, the Canadian Scleroderma Research Group, Baron M. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int 2009; 30: 1205 – 10.en_US
dc.identifier.citedreferenceBassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 2011; 50: 762 – 67.en_US
dc.identifier.citedreferenceSuarez‐Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 2007; 34: 1718 – 26.en_US
dc.identifier.citedreferenceStamm TA, Mattsson M, Mihai C, Stocker J, Binder A, Bauernfeind B, et al. Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries. Ann Rheum Dis 2011; 70: 1074 – 9.en_US
dc.identifier.citedreferenceWare JE Jr, Snow KK, Kosinski M, Gandek B. SF‐36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.en_US
dc.identifier.citedreferenceGneiting T, Raftery A. Strictly proper scoring rules. J Am Stat Assoc 2007; 102: 359 – 78.en_US
dc.identifier.citedreferenceNagelkerke NG. A note on a general definition of the coefficient of determination. Biometrika 1991; 78: 691 – 2.en_US
dc.identifier.citedreferencePope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351 – 8.en_US
dc.identifier.citedreferenceFurst D, Khanna D, Matucci‐Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis: continuing progress in developing clinical measures of response. J Rheumatol 2007; 34: 1194 – 200.en_US
dc.identifier.citedreferenceFries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137 – 45.en_US
dc.identifier.citedreferenceMerkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, et al, for the CAT‐192 Research Group and the Scleroderma Clinical Trials Consortium. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum 2008; 59: 699 – 705.en_US
dc.identifier.citedreferenceMerkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al, for the Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 2410 – 20.en_US
dc.identifier.citedreferenceKhanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, et al, for the Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2009; 60: 1102 – 11.en_US
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66.en_US
dc.identifier.citedreferenceMerkel PA, Clements PJ, Reveille JD, Suarez‐Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 1630 – 47.en_US
dc.identifier.citedreferenceClements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high‐dose versus low‐dose penicillamine trial. Arthritis Rheum 2000; 43: 2445 – 54.en_US
dc.identifier.citedreferenceSteen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437 – 44.en_US
dc.identifier.citedreferenceAmjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al, for the Investigators of the D‐Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double‐blind, randomized controlled trials. Arthritis Rheum 2009; 60: 2490 – 8.en_US
dc.identifier.citedreferenceVan der Heijde DM, van 't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 177 – 81.en_US
dc.identifier.citedreferenceLuijten KM, Tekstra J, Bijlsma JW, Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012; 11: 326 – 9.en_US
dc.identifier.citedreferenceSymmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al, and Members of the British Isles Lupus Assessment Group (BILAG). Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988; 69: 927 – 37.en_US
dc.identifier.citedreferenceBombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630 – 40.en_US
dc.identifier.citedreferenceValentini G, D'Angelo S, Della RA, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003; 62: 904 – 5.en_US
dc.identifier.citedreferenceMedsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159 – 67.en_US
dc.identifier.citedreferenceGiannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202 – 9.en_US
dc.identifier.citedreferenceSteen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol 2003; 21 Suppl 29: 29 – 31.en_US
dc.identifier.citedreferenceHoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: 42 – 50.en_US
dc.identifier.citedreferenceIoannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta‐analysis of individual patient data. Am J Med 2005; 118: 2 – 10.en_US
dc.identifier.citedreferenceElhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta‐analysis of cohort studies. Rheumatology (Oxford) 2012; 51: 1017 – 26.en_US
dc.identifier.citedreferenceKhanna D, Kowal‐Bielecka O, Khanna PP, Lapinska A, Asch SM, Wenger N, et al. Quality indicator set for systemic sclerosis. Clin Exp Rheumatol 2011; 29 Suppl 65: 33 – 9.en_US
dc.identifier.citedreferenceKhanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, et al, for the Investigators in CRISS and EPOSS. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36: 2356 – 61.en_US
dc.identifier.citedreferenceKhanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703 – 9.en_US
dc.identifier.citedreferenceKhanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007; 9: 151 – 7.en_US
dc.identifier.citedreferenceChung L, Denton CP, Distler O, Furst DE, Khanna D, Merkel PA. Clinical trial design in scleroderma: where are we and where do we go next? Clin Exp Rheumatol 2012; 30 Suppl 71: 97 – 102.en_US
dc.identifier.citedreferenceAbraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26: 587 – 95.en_US
dc.identifier.citedreferenceNagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) 2015; 54: 1944 – 53.en_US
dc.identifier.citedreferenceClements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281 – 5.en_US
dc.identifier.citedreferenceVan der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916 – 20.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr22804.pdf
Size:
776.7KB
Format:
PDF
View/Open
Name:
acr22804_am.pdf
Size:
1.328MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.